AstraZeneca (XTER:ZEG) Other Financing : €118 Mil (TTM As of Mar. 2025)

View and export this data going back to 2001. Start your Free Trial

What is AstraZeneca Other Financing?

AstraZeneca's Other Financing for the three months ended in Mar. 2025 was €96 Mil.

AstraZeneca's Other Financing for the trailing twelve months (TTM) ended in Mar. 2025 was €118 Mil.

AstraZeneca Other Financing Historical Data

The historical data trend for AstraZeneca's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AstraZeneca Other Financing Chart

AstraZeneca Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Financing

Get a 7-Day Free Trial

-83.02

-157.53

-988.37

-812.46

-780.24

AstraZeneca Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Other Financing	Get a 7-Day Free Trial															-773.72	-	21.62	-	96.20

AstraZeneca Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €118 Mil.

AstraZeneca Other Financing Related Terms

Thank you for viewing the detailed overview of AstraZeneca's Other Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

AstraZeneca Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AstraZeneca PLC (XTER:ZEG) » Definitions » Other Financing

Comparable Companies

Traded in Other Exchanges

AZNCF:USA AZN:USA AZN:Sweden AZNN:Mexico AZNl:UK AZN:UK A1ZN34:Brazil AZNA:Austria AZN:Argentina

Address

1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA

Website

https://www.astrazeneca.com

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.

AstraZeneca Headlines

No Headlines